AbbVie Reports Three-Year SELECT-COMPARE Data for Rinvoq in Rheumatoid Arthritis

AbbVie today presented three-year follow-up data from the Phase 3 SELECT-COMPARE trial evaluating Rinvoq (upadacitinib) versus adalimumab in patients with active rheumatoid arthritis who had an inadequate response to methotrexate. The data showed that Rinvoq maintained significantly higher rates of disease remission compared to adalimumab over three years.